See more : Yuexiu Real Estate Investment Trust (YUXXF) Income Statement Analysis – Financial Results
Complete financial analysis of Global Wellness Strategies Inc. (GWSFF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Global Wellness Strategies Inc., a leading company in the Financial – Credit Services industry within the Financial Services sector.
- Career Point Limited (CAREERP.NS) Income Statement Analysis – Financial Results
- Nickel Creek Platinum Corp. (NCPCF) Income Statement Analysis – Financial Results
- The Parkmead Group plc (PMG.L) Income Statement Analysis – Financial Results
- Anton Oilfield Services Group (3337.HK) Income Statement Analysis – Financial Results
- Sinopec Kantons Holdings Limited (0934.HK) Income Statement Analysis – Financial Results
Global Wellness Strategies Inc. (GWSFF)
Industry: Financial - Credit Services
Sector: Financial Services
Website: https://globalwellnessstrategies.com
About Global Wellness Strategies Inc.
Global Wellness Strategies Inc. formerly known as Redfund Capital Corp. is an incubator and accelerator firm specializing in incubation. The firm seeks to invest in the public and private sectors that focus on preventative health, wellness issues and related consumer products. The firm seeks to invest in Canada. The firm also provides debt financing facility. Global Wellness Strategies Inc. was incorporated in 1998 and is headquartered in Vancouver, Canada with an additional office in Vancouver, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 101.87K | 112.28K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.29M | 1.25M |
| Cost of Revenue | 2.67K | 1.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.05M | 1.59M |
| Gross Profit | -2.67K | -1.51K | 101.87K | 112.28K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.76M | -336.14K |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -15.63% | -26.85% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 54.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.38M | 3.88M | 696.31K | 2.82M | 3.30M | 186.84K | 114.22K | 79.04K | 74.22K | 69.01K | 126.12K | 135.34K | 296.09K | 2.23M | 3.50M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 56.60K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.38M | 3.88M | 696.31K | 2.82M | 3.30M | 186.84K | 114.22K | 79.04K | 74.22K | 69.01K | 126.12K | 135.34K | 296.09K | 2.23M | 3.50M |
| Other Expenses | 0.00 | 0.00 | 97.42K | 268.21K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.38M | 3.88M | 696.31K | 2.82M | 3.30M | 186.84K | 114.22K | 79.04K | 128.57K | 69.01K | 126.12K | 136.38K | 298.15K | 2.41M | 3.64M |
| Cost & Expenses | 1.38M | 3.88M | 696.31K | 2.82M | 3.30M | 186.84K | 114.22K | 79.04K | 128.57K | 69.01K | 126.12K | 136.38K | 298.15K | 15.46M | 5.23M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 2.62K | 1.49K | 0.00 | 560.00 | 0.00 | 0.00 | 258.00 | 544.00 | 0.00 | 0.00 | 2.02M | 1.63M |
| Depreciation & Amortization | -8.95K | -296.48K | 877.96K | -67.31K | 161.14K | 52.52K | 22.82K | 25.95K | -11.00K | 0.00 | 544.00 | 1.04K | 2.06K | 1.74M | 327.35K |
| EBITDA | -1.39M | -4.18M | 281.57K | -2.78M | -3.30M | -186.84K | -114.22K | -53.09K | -139.56K | -69.01K | -126.12K | -135.34K | -296.09K | -2.35M | -3.57M |
| EBITDA Ratio | 0.00% | 0.00% | 276.40% | -2,472.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -20.84% | -285.51% |
| Operating Income | -1.38M | -3.88M | -596.39K | -2.71M | -3.30M | -186.84K | -114.22K | -79.04K | -128.57K | -69.01K | -126.66K | -306.09K | -298.15K | -6.65M | -6.34M |
| Operating Income Ratio | 0.00% | 0.00% | -585.43% | -2,412.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -58.94% | -506.41% |
| Total Other Income/Expenses | 10.87K | 298.05K | -778.60K | 338.14K | -1.49K | 0.00 | -798.00 | -25.95K | 11.00K | -258.00 | 2.34K | 26.68K | 0.00 | -5.49M | -675.43K |
| Income Before Tax | -1.37M | -3.58M | -1.37M | -2.37M | -3.30M | -186.84K | -115.02K | -104.99K | -117.57K | -69.27K | -124.32K | -279.42K | -298.15K | -12.14M | -7.02M |
| Income Before Tax Ratio | 0.00% | 0.00% | -1,349.72% | -2,111.26% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -107.60% | -560.36% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.17M | -1.39M | -54.70K |
| Net Income | -1.37M | -3.58M | -1.37M | -2.37M | -3.30M | -186.84K | -115.02K | -104.99K | -117.57K | -69.27K | -124.32K | -279.42K | -6.47M | -8.53M | -5.33M |
| Net Income Ratio | 0.00% | 0.00% | -1,349.72% | -2,111.26% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -75.57% | -425.53% |
| EPS | -0.05 | -0.23 | -0.10 | -0.20 | -0.35 | -0.04 | -0.09 | -0.03 | -0.04 | -0.04 | -0.08 | -0.20 | -11.50 | -29.07 | -25.39 |
| EPS Diluted | -0.05 | -0.23 | -0.10 | -0.20 | -0.35 | -0.04 | -0.09 | -0.03 | -0.04 | -0.04 | -0.08 | -0.20 | -11.50 | -29.07 | -25.39 |
| Weighted Avg Shares Out | 27.15M | 15.87M | 13.83M | 12.12M | 9.45M | 5.04M | 1.33M | 3.27M | 3.27M | 1.65M | 1.49M | 1.43M | 562.53K | 293.42K | 209.81K |
| Weighted Avg Shares Out (Dil) | 27.15M | 15.87M | 13.83M | 12.12M | 9.45M | 5.04M | 1.33M | 3.27M | 3.27M | 1.65M | 1.49M | 1.43M | 562.53K | 293.42K | 209.81K |
XTACY Therapeutics Announces Debt Settlement
Source: https://incomestatements.info
Category: Stock Reports